Christian Doppler Laboratory for Allergy Research, Medical University of Vienna, Vienna, Austria.
J Allergy Clin Immunol. 2011 Apr;127(4):860-4. doi: 10.1016/j.jaci.2011.02.016.
This year we are celebrating not only the centenary of allergen-specific immunotherapy but also the 10-year anniversary of the first administration of recombinant allergen-based vaccines to allergic patients. By using recombinant DNA technology, defined and safe allergy vaccines can be produced that allow us to overcome many, if not all, of the problems associated with the use of natural allergen extracts, such as insufficient quality, allergenic activity, and poor immunogenicity. Here we provide an update of clinical studies with recombinant allergen-based vaccines, showing that some of these vaccines have undergone successful clinical evaluation up to phase III studies. Furthermore, we introduce a strategy for allergen-specific immunotherapy based on recombinant fusion proteins consisting of viral carrier proteins and allergen-derived peptides without allergenic activity, which holds the promise of being free of side effects and eventually being useful for prophylactic vaccination.
今年，我们不仅庆祝了变应原特异性免疫治疗的百年纪念，也庆祝了首个重组变应原疫苗用于过敏性患者治疗的十周年。通过使用重组 DNA 技术，可以生产出明确且安全的变应原疫苗，使我们能够克服与天然变应原提取物使用相关的许多问题，如质量不足、变应原活性和低免疫原性。在这里，我们提供了重组变应原疫苗的临床研究更新，表明其中一些疫苗已经成功地进行了 III 期临床试验评估。此外，我们还介绍了一种基于由病毒载体蛋白和无变应原活性的变应原衍生肽组成的重组融合蛋白的变应原特异性免疫治疗策略，该策略有望无副作用，并最终可用于预防性接种。
